Disc Medicine Announces Presentation of Clinical Data from Phase 1 of the First DISC-0974 Human Study at the European Hematology Association (EHA) Congress 2022

Disc Medicine Announces Presentation of Clinical Data from Phase 1 of the First DISC-0974 Human Study at the European Hematology Association (EHA) Congress 2022


Poster highlighting safety, tolerability, pharmacokinetics and effects on hepcidin and measurement of iron metabolism DISC-0974 from a phase 1 study in healthy volunteers

WATERTOWN, Mass., May 16, 2022 / PRNewswire / – Disc Medicine, a biotechnology company dedicated to discovering and developing new therapeutic candidates for major and debilitating hematology, announced today that DISC-0974 clinical data will be presented at the upcoming annual European Hematology Association (EHA). The congress takes place in Vienna 9-12 June. The presentation will present the initial results of an ongoing phase 1a, single-dose placebo-controlled study in healthy volunteers. This study was designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of both intravenous and subcutaneous DISC-0974. DISC-0974 showed signs of target involvement and iron mobilization and was generally well tolerated. The abstract is available on the EHA website at www.ehaweb.org and the poster will be published on the EHA Congress platform on June 10, 2022.

Disc Medicine is a hematology company that uses new knowledge in hepcidin biology to address the inefficient production of red blood cells (erythropoiesis) in hematological diseases. Focusing on the hepcidin pathway, a major regulator of iron metabolism, Disc promotes first-class therapies to transform the treatment of hematological diseases. (PRNewsfoto / Disc Medicine)

Presentation details:

Abstract: P1559
Title: DISC-0974, the first human anti-hemojuvelin monoclonal antibody, lowers serum hepcidin levels and mobilizes iron in healthy participants
Session name: Iron metabolism, deficiency and overload
Session date and time: Friday, June 10, 202216:30 – 17:45 CEST (10: 30–11: 45 ET)

About DISC-0974

DISC-0974 is a first-class research monoclonal antibody designed to suppress hepcidin production by inhibiting the hemojuvelin (HJV) co-receptor, a highly selective and critical target of the hepcidin pathway with biological activity that has been verified by human genetic evidence. Hepcidin is the primary regulatory hormone of iron homeostasis and plays a central role by limiting iron absorption and preventing its excretion from internal iron stores. DISC-0974 is currently being studied in a phase 1 clinical study in healthy volunteers and is being developed as a potential treatment for inflammatory anemia by suppressing hepcidin and increasing the availability of iron for erythropoiesis.

DISC-0974 is a research therapy that is not approved for use in any country. The disk acquired global rights to DISC-0974 and related molecules under a license agreement from AbbVie v October 2019.

About disc medicine

Disc Medicine is a biopharmaceutical company in the clinical phase that is dedicated to transforming the lives of patients with hematological disorders. We are building a portfolio of innovative, first-class therapeutic candidates who influence the basic pathways of red blood cell biology. Disc Medicine is committed to developing treatments that enhance and bring hope to many patients with hematology. For more information, please visit www.discmedicine.com.

Cision

Cision

View original multimedia downloads: https://www.prnewswire.com/news-releases/disc-medicine-announces-presentation-of-clinical-data-from-first-in-human-phase-1-study- of -disc-0974-at-european-hematology-association-eha-2022-congress-301548111.html

SOURCE Disk Medicine



Source link

Leave a Comment

Your email address will not be published.